Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Statins use and COVID-19 outcomes in hospitalized patients
Samuel K. Ayeh, Enoch J. Abbey, Banda A. A. Khalifa, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0256899-e0256899
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study
Hamideh Kouhpeikar, Hamidreza Khosaravizade Tabasi, Zahra Khazir, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 45
Lipid Raft Integrity and Cellular Cholesterol Homeostasis Are Critical for SARS-CoV-2 Entry into Cells
Ahmed Bakillah, Fatimah Al Hejji, Abdulrahman Almasaud, et al.
Nutrients (2022) Vol. 14, Iss. 16, pp. 3417-3417
Open Access | Times Cited: 39
Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic
Aliakbar Hasankhani, Abolfazl Bahrami, Negin Sheybani, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 51
Survival of the hospitalized patients with COVID‐19 receiving atorvastatin: A randomized clinical trial
Majid Ghafoori, Hassan Saadati, Mohammadreza Taghavi, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3160-3168
Open Access | Times Cited: 27
Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial
Hajar Shokri‐Afra, Sudabe Baghery moghadam, Ziaeddin Oladi, et al.
Journal of Reports in Pharmaceutical Sciences (2025) Vol. 13, Iss. 1
Open Access
Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study
Kim Bouillon, Bérangère Baricault, Laura Semenzato, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 12
Open Access | Times Cited: 19
Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients
Ut-Sam Lao, Chak-Fun Law, Daniel T. Baptista‐Hon, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 18, pp. 5454-5454
Open Access | Times Cited: 19
Acute and Long-Term Consequences of COVID-19 on Arterial Stiffness—A Narrative Review
Ioana Mădălina Zota, Cristian Stătescu, Radu Andy Sascău, et al.
Life (2022) Vol. 12, Iss. 6, pp. 781-781
Open Access | Times Cited: 16
Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Tayyab Shah, Marianne McCarthy, Irem Nasir, et al.
BMJ Open (2023) Vol. 13, Iss. 2, pp. e067910-e067910
Open Access | Times Cited: 9
A practical treatment for COVID‐19 and the next pandemic
Jahar Bhattacharya, Robert Booy, Arturo Casadevall, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 11
Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy
Vyoma Snehal Trivedi, Albert Frank Magnusen, Reena Rani, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14340-14340
Open Access | Times Cited: 11
Prior Statin vs In-Hospital Statin Usage in Severe COVID-19: Review and Meta-Analysis
Iad Alhallak, Hakan Paydak, Jawahar L. Mehta
Current Problems in Cardiology (2023) Vol. 48, Iss. 9, pp. 101810-101810
Open Access | Times Cited: 6
Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations
Beatrice A. Golomb, Junhee Han, Peter H. Langsjoen, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 14, pp. 4659-4659
Open Access | Times Cited: 6
Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients
Megan M. Sperry, Tomiko Oskotsky, Ivana Marić, et al.
PLoS Computational Biology (2023) Vol. 19, Iss. 5, pp. e1011050-e1011050
Open Access | Times Cited: 5
Lipid compartments and lipid metabolism as therapeutic targets against coronavirus
Daniella Cesar-Silva, Filipe S. Pereira‐Dutra, Ana L.M. Giannini, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Lipid profile changes in patients with COVID-19 referred to medical centers in Kermanshah, Iran; a case–control study
Shahab Changaripour, Hosna Sarvazad, Maryam Barghi, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 2, pp. 030006052210786-030006052210786
Open Access | Times Cited: 9
Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19
Chengyu Liu, Wanyao Yan, Jiajian Shi, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 9
Impact of Statin or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker on In-Hospital Mortality of COVID-19 Patients
Mohsen Gholinataj Jelodar, Samaneh Mirzaei, Majid Haji Maghsoudi
Journal of Pharmaceutical Care (2024)
Open Access | Times Cited: 1
Treating COVID-19: Targeting the Host Response, Not the Virus
David S. Fedson
Life (2023) Vol. 13, Iss. 3, pp. 712-712
Open Access | Times Cited: 4
Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial
Azita H. Talasaz, Parham Sadeghipour, Hooman Bakhshandeh, et al.
Thrombosis and Haemostasis (2023) Vol. 123, Iss. 07, pp. 723-733
Open Access | Times Cited: 4
Association of antecedent statin use on 30-day, 60-day and 90-day mortality among Mississippi Medicaid beneficiaries diagnosed with COVID-19
Yiran Rong, Swarnali Goswami, O Eriakha, et al.
BMJ Open (2023) Vol. 13, Iss. 11, pp. e076195-e076195
Open Access | Times Cited: 3
Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications
Ching-Tse Ting, Bor‐Sen Chen
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3649-3649
Open Access | Times Cited: 5
Statins Use in Patients with Cardiovascular Diseases and COVID-19 Outcomes: An Italian Population-Based Cohort Study
Ippazio Cosimo Antonazzo, Carla Fornari, Davide Rozza, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 24, pp. 7492-7492
Open Access | Times Cited: 5
Statins - From Lipid-Lowering Benefits to Pleiotropic Effects

IntechOpen eBooks (2023)
Open Access | Times Cited: 2
Efficacy and limitations of repurposed drugs and vaccines for COVID-19
Nensina Murmu, Mrinmoy Sarkar, Sananda Dey, et al.
Journal of Medicine Surgery and Public Health (2023) Vol. 2, pp. 100041-100041
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top